-
Daiichi Sankyo2020-08-03 09:32:24Daiichi Sankyo’s VANFLYTA® Receives Approval in Japan for the Treatment of Relapsed/Refractory FLT3-ITD AML
-
Daiichi Sankyo2019-08-07 13:30:01Daiichi Sankyo Presents Preliminary Phase 1 Data for TROP2 Targeting ADC DS-1062 in Patients with Non-Small
-
Daiichi Sankyo2019-08-07 13:30:01Daiichi Sankyo Presents Preliminary Phase 1 Data for HER3 Targeting ADC U3-1402 in Patients with EGFR Mutated
-
Daiichi Sankyo2019-05-28 13:30:01Daiichi Sankyo Data Presentations at 2019 ASCO Annual Meeting Highlight Depth of ADC Pipeline and Promises of
-
Daiichi Sankyo2019-05-28 13:30:01Daiichi Sankyo Announces [Fam-] Trastuzumab Deruxtecan Demonstrated Clinically Meaningful Response in Patients
-
Daiichi Sankyo2019-10-15 11:27:12Daiichi Sankyo Announces Two Lancet Oncology Publications of Phase 1 Dose Expansion Results of [Fam-]
-
Daiichi Sankyo2019-05-28 13:30:01Daiichi Sankyo’s EZH1/2 Dual Inhibitor Valemetostat (DS-3201) Receives SAKIGAKE Designation for Treatment of
-
Daiichi Sankyo2019-10-15 11:25:54EMA Validates Daiichi Sankyo’s Marketing Authorization Application for Pexidartinib for Treatment of Patients
-
Daiichi Sankyo2019-05-28 13:30:01Daiichi Sankyo and AstraZeneca Announce Global Development and Commercialization Collaboration for Daiichi
-
Daiichi Sankyo2020-08-03 09:33:03Bempedoic Acid CLEAR Serenity Study Results Published in the JAHA Demonstrated Significant LDL-Cholesterol